Találati lista | Tudóstér

001-es BibID:	BIBFORM046701
035-os BibID:	WOS:000181678300004 PMID:12637459
Első szerző:	Nabholtz, Jean-Marc
Cím:	Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial / Jean-Marc Nabholtz, Carla Falkson, Daniel Campos, Janos Szanto, Miguel Martin, Stephen Chan, Tadeuz Pienkowski, Jerzy Zaluski, Tamas Pinter, Maciej Krzakowski, Daniel Vorobiof, Robert Leonard, Ian Kennedy, Nacer Azli, Michael Murawsky, Alessandro Riva, Pierre Pouillart, TAX 306 Study Group
Dátum:	2003
ISSN:	0732-183X 1527-7755
Megjegyzések:	This randomized, multicenter, phase III study compared doxorubicin and docetaxel (AT) with doxorubicin and cyclophosphamide (AC) as first-line chemotherapy (CT) in metastatic breast cancer (MBC). PATIENTS AND METHODS: Patients (n = 429) were randomly assigned to receive doxorubicin 50 mg/m(2) plus docetaxel 75 mg/m(2) (n = 214) or doxorubicin 60 mg/m(2) plus cyclophosphamide 600 mg/m(2) (n = 215) on day 1, every 3 weeks for up to eight cycles. RESULTS: Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048). The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009). The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%). Overall survival (OS) was comparable in both arms. Grade 3/4 neutropenia was frequent in both groups, although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01). Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%). CONCLUSION: AT significantly improves TTP and ORR compared with AC in patients with MBC, but there is no difference in OS. AT represents a valid option for the treatment of MBCújratöltve - BIBFORM034164
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Journal of Clinical Oncology. - 21 : 6 (2003), p. 968-975. -
További szerzők:	Falkson, Carla Campos, Daniel Szántó János (1949-) (onkológus szakorvos) Martin, Miguel Chan, Stephen Pienkowski, Tadeuz Zaluski, Jerzy Pintér Tamás Krzakowski, Maciej Vorobiof, Daniel Leonard, Robert Kennedy, Ian Azli, Nacer Murawsky, Michael Riva, Alessandro Pouillart, Pierre TAX 306 Study Group
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM002773
Első szerző:	Tsakiris, Ioannis (orvos)
Cím:	The presence of carboxypeptidase-M in tumour cells signifies epidermal growth factor receptor expression in lung adenocarcinomas : the coexistence predicts a poor prognosis regardless of EGFR levels / Tsakiris I., Soos G., Nemes Z., Sz. Kiss S., Andras C., Szantó J., Dezso B.
Dátum:	2008
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Journal of Cancer Research and Clinical Oncology. - 134 : 4 (2008), p. 439-451. -
További szerzők:	Soós Györgyike (1959-) (pathológus) Nemes Zoltán (1942-) (patológus) Kiss Sándor, Sz. (1946-) (sebész) András Csilla (1961-) (onkológus szakorvos) Szántó János (1949-) (onkológus szakorvos) Dezső Balázs (1951-) (pathológus)
Internet cím:	elektronikus változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM046706
035-os BibID:	WOS:000227367900011 PMID:15735116
Első szerző:	Zielinski, Christoph
Cím:	Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer : a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial / Christoph Zielinski, Semir Beslija, Zrinka Mrsic-Krmpotic, Marzena Welnicka-Jaskiewicz, Christoph Wiltschke, Zsuzsanna Kahan, Mislav Grgic, Valentina Tzekova, Moshe Inbar, Jozika Cervek, Ivan Chernozemsky, Janos Szanto, Stanislav Spanik, Maria Wagnerova, Nicolae Ghilezan, Janusz Pawlega, Damir Vrbanec, Dmitry Khamtsov, Victoria Soldatenkova, Thomas Brodowicz
Dátum:	2005
ISSN:	0732-183X 1527-7755
Megjegyzések:	BACKGROUND: The objectives of this phase III trial were to compare the time to progressive disease (TtPD), overall response rate (ORR), overall survival, and toxicity of gemcitabine, epirubicin, and paclitaxel (GET) versus fluorouracil (FU), epirubicin, and cyclophosphamide (FEC) as first-line therapy in patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: Female patients aged 18 to 75 years with stage IV and measurable MBC were enrolled and randomly assigned to either gemcitabine (1,000 mg/m(2), days 1 and 4), epirubicin (90 mg/m(2), day 1), and paclitaxel (175 mg/m(2), day 1) or FU (500 mg/m(2), day 1), epirubicin (90 mg/m(2), day 1), and cyclophosphamide (500 mg/m(2), day 1). Both regimens were administered every 21 days for a maximum of eight cycles. RESULTS: Between October 1999 and November 2002, 259 patients (GET, n = 124; FEC, n = 135) were enrolled. Baseline characteristics were well balanced across treatment arms. After a median of 20.4 months of follow-up, median TtPD was 9.1 months and 9.0 months in the GET and FEC arms, respectively (P = .557). The ORR was 62.3% in the GET arm (n = 114) and 51.2% in the FEC arm (n = 129; P = .093). Grade 3 and 4 toxicities, including neutropenia, thrombocytopenia, anemia, stomatitis, neurosensory toxicity, and allergy, occurred significantly more often in the GET arm. CONCLUSION: No significant differences in terms of TtPD and ORR were observed between the two treatment arms. Treatment-related toxicity was higher in the GET arm.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Journal of Clinical Oncology. - 23 : 7 (2005), p. 1401-1408. -
További szerzők:	Beslija, Semir Mrsic-Krmpotic, Zrinka Welnicka-Jaskiewicz, Marzena Wiltschke, Christoph Kahán Zsuzsa Grgic, Mislav Tzekova, Valentina Inbar, Moshe Cervek, Jozika Chernozemsky, Ivan Szántó János (1949-) (onkológus szakorvos) Spanik, Stanislav Wagnerova, Maria Ghilezan, Nicolae Pawlega, Janusz Vrbanec, Damir Khamtsov, Dmitry Soldatenkova, Victoria Brodowicz, Thomas
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: